07:41 AM EDT, 07/18/2025 (MT Newswires) -- Bristol Myers Squibb ( BMY ) said Friday that its phase 3 independence trial of Reblozyl in myelofibrosis-associated anemia failed to meet its primary endpoint of transfusion independence.

Several secondary endpoints showed meaningful benefits, including reduced transfusion burden and increased hemoglobin levels, the company said.

Adverse events were consistent with Reblozyl's known safety profile, it said.

Bristol Myers Squibb ( BMY ) also said it will engage with the US Food and Drug Administration and EMA to explore possible marketing applications.